Plugging One VC Gap

Two years ago, the UK's publicly-funded Medical Research Council set up a new venture fund with a right of first refusal to all MRC-funded technology. Its British VC competitors greeted the newcomer, which claimed to want to fill a gap in seed-stage investing, coolly--they felt that no such gap existed and that UK Medical Ventures Fund would have an unfair advantage. Whether they're still jealous is uncertain, but they are doing deals with the new fund, which has significantly stepped up the rate at which MRC technology is transferred to the marketplace.

Two years ago, the UK's publicly-funded Medical Research Council (MRC) set up a new venture fund with an apparently unfair advantage: right of first refusal to all MRC-funded technology (see "Her Majesty's VC,"START-UP, January 1998 [A#1998900013).

MRC had looked around for existing venture capital firms to which it could offer the privilege, but when it didn't...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business

Supernus Secures Sage With CVR-Supported Deal

 

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By 

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.